Skip to main content
Premium Trial:

Request an Annual Quote

New York Approves Natera's CLIA Laboratory

NEW YORK (GenomeWeb News) – Natera today announced that New York has issued a permit for the company's CLIA laboratory, allowing Natera to offer its preconception and prenatal tests to expecting parents in the state.

The New York State Department of Health issued a clinical laboratory permit for the company's CLIA-certified laboratory in San Carlos, Calif. Approval includes Natera's Panorama non-invasive prenatal test for fetal aneuploidies, the firm said.

The test, launched earlier this year, uses a blood draw to detect trisomy 21, 18, and 13, as well as monosomy X, triploidy, and sex chromosome aneuploidies. It employs Natera's algorithm called Next Generation Aneuploidy Testing Using SNPs to analyze cell-free DNA from both the mother and the fetus.

Natera last week announced an agreement with DiagCor to bring Panorama to Hong Kong. It has deals with Quest Diagnostics, Bio-Reference Laboratories, and Arup Laboratories to offer its test in the US.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.